>owl v fox, see link to the company's abstract from the American meeting. go to the bottom of the diagram, there in black and white it says "first blinded futility analysis" , 72 patients week 35. it'll be done on proteinuria difference according to the company (yes I do read ANNs)
https://www.asn-online.org/education/kidneyweek/2023/program-abstract.aspx?controlId=3965367
> a futility interim analysis is a go/no-go event. No go usually means study is terminated. I thought you understood that.
>not much point shooting the messenger, simply pointing out the facts of the trial design as presented by the company, not unusual design as futility analysis is quite common in phase3
Ann: ACTION3 IND Approved in China, page-34
-
- There are more pages in this discussion • 198 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
-0.035(6.42%) |
Mkt cap ! $280.3M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.0¢ | 50.0¢ | $1.454M | 2.822M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 544899 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 104681 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |